Figure_3.tif (533.49 kB)
CCND1 amplification and relapse-free survival.
figure
posted on 2013-12-19, 03:31 authored by Dana Keilty, Marguerite Buchanan, Katerina Ntapolias, Olga Aleynikova, Dongsheng Tu, Xiao Li, Lois Shepherd, Vivien Bramwell, Mark BasikRFS for patients with CCND1 gene amplification or not, showing benefit from tamoxifen in both groups. Kaplan-Meier curves for RFS, tamoxifen vs. placebo in patients with CCDN1 gene non-amplified (“low CCND1”) (A) and amplified (“high CCND1”) (B) tumors. Adjusted HRs are included for the comparison of tamoxifen vs. placebo in each group.
